National Comprehensive Cancer Network
Updated Colon and Rectal Cancer Guidelines Include Options for Surveillance and Shortened Duration of Adjuvant Treatment
The National Comprehensive Cancer Network has overhauled its guidelines for the management of colon and rectal cancers.
Updated NCCN Breast Cancer Guidelines Add Options for HER2-Positive Disease, Emphasize CDK4/6 Inhibition in Hormone-Sensitive Cancer
The updated guidelines from the National Comprehensive Cancer Network on the management of breast expand treatment options in HER2-positive disease to include extended adjuvant neratinib after completion of trastuzumab in patients with high risk of recurrence and recognize a third CDK 4/6 inhibitor in hormone-sensitive breast cancer.
The updated guidelines from the National Comprehensive Cancer Network on the management of metastatic non–small cell lung cancer reflect the addition of osimertinib as a first-line option in patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation and as subsequent therapy in patients whose disease progresses following another tyrosine kinase inhibitor if they develop a T790M resistance mutation.